Antibody clones and dilution ratio.

BackgroundNon-small cell lung cancer (NSCLC) has a high incidence, with most patients diagnosed beyond the optimal surgical window. Improving survival rates is critical to reducing lung cancer mortality, and identifying immune checkpoints is vital for prognosis stratification.ObjectiveTo investigate the expression of CD47 in NSCLC and its relationship with tumor-associated macrophage infiltration.MethodsA retrospective analysis was conducted on 50 NSCLC patients treated between January 2014 and June 2018. Immunohistochemistry and confocal microscopy assessed CD47 expression in tumor and adjacent tissues, while immunofluorescence evaluated CD47 on tumor-infiltrating T lymphocytes. Kaplan-Meier survival analysis and Cox regression identified prognostic factors, and PLA technology examined CD47’s interaction with VEGFR and CD36.ResultsCD47 positivity in tumor tissues (52%) was significantly higher than in adjacent tissues (20%) (PPPConclusionCD47 positivity correlates with poor prognosis and increased TAM infiltration, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC.